I am a
Home I AM A Search Login

Papers of the Week

Papers: 10 Feb 2024 - 16 Feb 2024

2024 Feb 09

Expert Opin Emerg Drugs


Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.


Pellesi L, Ashina M, Martelletti P


The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC) receptor for migraine prevention.